Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
- Abbott plans to spin off its nutrition unit as a standalone public company
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- Anthropic logged net loss of over $80 billion in first half of 2026
Johnson & Johnson Reports Q3 2021 Results
October 19, 2021 6:25 AM EDTNEW BRUNSWICK, N.J., Oct. 19, 2021 /PRNewswire/ --Â Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. "Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health," said Alex Gorsky, Chairman and Chief Executive Officer. "In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in... More



